A Study of S-892216 in Participants With COVID-19
NCT06928051
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
282
Enrollment
INDUSTRY
Sponsor class
Conditions
COVID-19
Interventions
DRUG:
S-892216
DRUG:
Placebo
Sponsor
Shionogi